blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1773822

EP1773822 - HETEROCYCLYLS AS SELECTIVE MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONISTS FOR THE TREATMENT OF OBESITY AND RELATED DISORDERS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  23.04.2010
Database last updated on 03.09.2024
Most recent event   Tooltip07.10.2011Lapse of the patent in a contracting state
New state(s): CY, TR		published on 09.11.2011  [2011/45]
Applicant(s)For all designated states
Schering Corporation
2000 Galloping Hill Road
Kenilworth, NJ 07033-0530 / US
[2009/25]
Former [2007/16]For all designated states
SCHERING CORPORATION
2000 Galloping Hill Road
Kenilworth, NJ 07033-0530 / US
Inventor(s)01 / SU, Jing
1398 Graymill Drive
Scotch Plains, NJ 07076 / US
02 / MCKITTRICK, Brian
14 Millbrook Road
New Vernon, NJ 07976 / US
03 / TANG, Haiqun
5 Waters Lane
Belle Meade, NJ 08502 / US
04 / SASIKUMAR, Thavalakulamgara, K.
21 Canterbury Lane
Edison, NJ 08820 / US
05 / QIANG, Li
261 Horizon Drive
Edison, NJ 08817 / US
 [2007/16]
Representative(s)Adams, Harvey Vaughan John, et al
Mathys & Squire LLP The Shard
32 London Bridge Street
London SE1 9SG / GB
[N/P]
Former [2007/16]Adams, Harvey Vaughan John, et al
Mathys & Squire 120 Holborn
London EC1N 2SQ / GB
Application number, filing date05773671.214.07.2005
[2007/16]
WO2005US25060
Priority number, dateUS20040588492P16.07.2004         Original published format: US 588492 P
[2007/16]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2006019957
Date:23.02.2006
Language:EN
[2006/08]
Type: A2 Application without search report 
No.:EP1773822
Date:18.04.2007
Language:EN
The application published by WIPO in one of the EPO official languages on 23.02.2006 takes the place of the publication of the European patent application.
[2007/16]
Type: B1 Patent specification 
No.:EP1773822
Date:17.06.2009
Language:EN
[2009/25]
Search report(s)International search report - published on:EP27.04.2006
ClassificationIPC:C07D409/12, C07D409/14, C07D417/12, C07D487/08
[2007/16]
CPC:
C07D487/08 (EP,US); A61P3/04 (EP); A61P3/06 (EP);
A61P3/10 (EP); A61P43/00 (EP); A61P5/50 (EP);
A61P9/12 (EP); C07D277/26 (EP,US); C07D277/28 (EP,US);
C07D333/20 (EP,US); C07D409/12 (EP,US); C07D409/14 (EP,US);
C07D417/12 (EP,US); C07D417/14 (EP,US) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2007/16]
Extension statesAL16.02.2007
BA16.02.2007
HR16.02.2007
MK16.02.2007
YU16.02.2007
TitleGerman:HETEROCYCLYLVERBINDUNGEN ALS SELEKTIVE ANTAGONISTEN AM REZEPTOR FÜR DAS MELANINKONZENTRIERENDE HORMON ZUR BEHANDLUNG VON OBESITAS UND VERWANDTEN ERKRANKUNGEN[2007/16]
English:HETEROCYCLYLS AS SELECTIVE MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONISTS FOR THE TREATMENT OF OBESITY AND RELATED DISORDERS[2007/16]
French:HETEROCYCLYLES UTILISES EN TANT QU'ANTAGONISTES DU RECEPTEUR DE L'HORMONE CONCENTRANT LA MELANINE POUR LE TRAITEMENT DE L'OBESITE ET DE TROUBLES ASSOCIES[2008/52]
Former [2007/16]NOUVEAUX HETEROCYCLYLES UTILISES EN TANT QU'ANTAGONISTES DU RECEPTEUR DE L'HORMONE CONCENTRANT LA MELANINE POUR LE TRAITEMENT DE L'OBESITE ET DE TROUBLES ASSOCIES
Entry into regional phase16.02.2007National basic fee paid 
16.02.2007Designation fee(s) paid 
16.02.2007Examination fee paid 
Examination procedure16.02.2007Examination requested  [2007/16]
03.08.2007Despatch of a communication from the examining division (Time limit: M06)
16.01.2008Reply to a communication from the examining division
25.08.2008Despatch of a communication from the examining division (Time limit: M04)
11.11.2008Reply to a communication from the examining division
15.12.2008Communication of intention to grant the patent
15.04.2009Fee for grant paid
15.04.2009Fee for publishing/printing paid
Opposition(s)18.03.2010No opposition filed within time limit [2010/21]
Fees paidRenewal fee
04.07.2007Renewal fee patent year 03
27.03.2008Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT17.06.2009
BE17.06.2009
CY17.06.2009
CZ17.06.2009
DK17.06.2009
EE17.06.2009
FI17.06.2009
LT17.06.2009
LV17.06.2009
PL17.06.2009
RO17.06.2009
SI17.06.2009
SK17.06.2009
TR17.06.2009
IE14.07.2009
LU14.07.2009
CH31.07.2009
LI31.07.2009
MC31.07.2009
BG17.09.2009
SE17.09.2009
GR18.09.2009
IS17.10.2009
PT17.10.2009
HU18.12.2009
[2011/44]
Former [2011/32]AT17.06.2009
BE17.06.2009
CZ17.06.2009
DK17.06.2009
EE17.06.2009
FI17.06.2009
LT17.06.2009
LV17.06.2009
PL17.06.2009
RO17.06.2009
SI17.06.2009
SK17.06.2009
IE14.07.2009
LU14.07.2009
CH31.07.2009
LI31.07.2009
MC31.07.2009
BG17.09.2009
SE17.09.2009
GR18.09.2009
IS17.10.2009
PT17.10.2009
HU18.12.2009
Former [2011/22]AT17.06.2009
BE17.06.2009
CZ17.06.2009
DK17.06.2009
EE17.06.2009
FI17.06.2009
LT17.06.2009
LV17.06.2009
PL17.06.2009
RO17.06.2009
SI17.06.2009
SK17.06.2009
IE14.07.2009
LU14.07.2009
CH31.07.2009
LI31.07.2009
MC31.07.2009
BG17.09.2009
SE17.09.2009
GR18.09.2009
IS17.10.2009
PT17.10.2009
Former [2011/01]AT17.06.2009
BE17.06.2009
CZ17.06.2009
DK17.06.2009
EE17.06.2009
FI17.06.2009
LT17.06.2009
LV17.06.2009
PL17.06.2009
RO17.06.2009
SI17.06.2009
SK17.06.2009
IE14.07.2009
CH31.07.2009
LI31.07.2009
MC31.07.2009
BG17.09.2009
SE17.09.2009
GR18.09.2009
IS17.10.2009
PT17.10.2009
Former [2010/40]AT17.06.2009
BE17.06.2009
CZ17.06.2009
DK17.06.2009
EE17.06.2009
FI17.06.2009
LT17.06.2009
LV17.06.2009
PL17.06.2009
RO17.06.2009
SI17.06.2009
SK17.06.2009
IE14.07.2009
CH31.07.2009
LI31.07.2009
MC31.07.2009
BG17.09.2009
SE17.09.2009
IS17.10.2009
PT17.10.2009
Former [2010/24]AT17.06.2009
BE17.06.2009
CZ17.06.2009
DK17.06.2009
EE17.06.2009
FI17.06.2009
LT17.06.2009
LV17.06.2009
PL17.06.2009
RO17.06.2009
SI17.06.2009
SK17.06.2009
CH31.07.2009
LI31.07.2009
MC31.07.2009
BG17.09.2009
SE17.09.2009
IS17.10.2009
PT17.10.2009
Former [2010/20]AT17.06.2009
BE17.06.2009
CZ17.06.2009
DK17.06.2009
EE17.06.2009
FI17.06.2009
LT17.06.2009
LV17.06.2009
PL17.06.2009
RO17.06.2009
SI17.06.2009
SK17.06.2009
MC31.07.2009
BG17.09.2009
SE17.09.2009
IS17.10.2009
PT17.10.2009
Former [2010/17]AT17.06.2009
BE17.06.2009
CZ17.06.2009
EE17.06.2009
FI17.06.2009
LT17.06.2009
LV17.06.2009
PL17.06.2009
RO17.06.2009
SI17.06.2009
SK17.06.2009
MC31.07.2009
BG17.09.2009
SE17.09.2009
IS17.10.2009
PT17.10.2009
Former [2010/12]AT17.06.2009
BE17.06.2009
CZ17.06.2009
EE17.06.2009
FI17.06.2009
LT17.06.2009
LV17.06.2009
PL17.06.2009
RO17.06.2009
SI17.06.2009
SK17.06.2009
MC31.07.2009
SE17.09.2009
IS17.10.2009
Former [2010/01]AT17.06.2009
FI17.06.2009
LT17.06.2009
LV17.06.2009
PL17.06.2009
SI17.06.2009
SE17.09.2009
Former [2009/52]AT17.06.2009
FI17.06.2009
LT17.06.2009
LV17.06.2009
SI17.06.2009
SE17.09.2009
Cited inInternational search[A]WO02057233  (SCHERING CORP [US]) [A] 1 * the whole document * * Example 27, Ar3 means arylene *;
 [DX]WO03047568  (SCHERING CORP [US]) [DX] 1-48 * examples 2,12-91,94-144,153-194,196-224,226-424; tables 1b,2 *;
 [AP]WO2005034947  (SCHERING CORP [US], et al) [AP] 1-48* claims 1-26 *;
 [X]  - BROWNING A, "Recent developments in the discovery of melanin-concentrating hormone antagonists: Novel antiobesity agents", EXPERT OPINION ON THERAPEUTIC PATENTS 2004 UNITED KINGDOM, (2004), vol. 14, no. 3, ISSN 1354-3776, pages 313 - 325, XP002365091 [X] 1-48 * abstract *

DOI:   http://dx.doi.org/10.1517/13543776.14.3.313
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.